Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maze Therapeutics (MAZE) Enterprise Value (2024 - 2026)

Maze Therapeutics' Enterprise Value history spans 3 years, with the latest figure at -$352.4 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 19.71% to -$352.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$352.4 million, a 19.71% decrease, with the full-year FY2025 number at -$341.9 million, down 73.73% from a year prior.
  • Enterprise Value hit -$352.4 million in Q1 2026 for Maze Therapeutics, down from -$341.9 million in the prior quarter.
  • Over the last five years, Enterprise Value for MAZE hit a ceiling of -$30.0 million in Q1 2024 and a floor of -$383.9 million in Q3 2025.
  • Historically, Enterprise Value has averaged -$243.2 million across 3 years, with a median of -$264.5 million in 2025.
  • Biggest five-year swings in Enterprise Value: crashed 880.49% in 2025 and later fell 19.71% in 2026.
  • Tracing MAZE's Enterprise Value over 3 years: stood at -$196.8 million in 2024, then tumbled by 73.73% to -$341.9 million in 2025, then fell by 3.06% to -$352.4 million in 2026.
  • Business Quant data shows Enterprise Value for MAZE at -$352.4 million in Q1 2026, -$341.9 million in Q4 2025, and -$383.9 million in Q3 2025.